| Literature DB >> 29262292 |
Viviana Lo Martire1, Sara Alvente1, Stefano Bastianini1, Chiara Berteotti1, Cristiano Bombardi2, Giovanna Calandra-Buonaura3, Sabina Capellari3, Gary Cohen4, Pietro Cortelli3, Laura Gasparini5, Quasar Padiath6, Alice Valli1, Giovanna Zoccoli1, Alessandro Silvani7.
Abstract
Autosomal dominant leukodystrophy (ADLD) is a rare adult-onset demyelinating disease caused by overexpression of lamin B1, a nuclear lamina filament. Early autonomic dysfunction involving the cardiovascular system before progressive somatic motor dysfunction is a striking feature of most cases of ADLD. In the Plp-FLAG-LMNB1 transgenic mouse model, lamin B1 overexpression in oligodendrocytes elicits somatic motor dysfunction and neuropathology akin to ADLD. Here, we investigate whether Plp-FLAG-LMNB1 mice also develop autonomic cardiovascular dysfunction before or after somatic motor dysfunction. We find that Plp-FLAG-LMNB1 mice have preserved cardiovascular responses to changes in wake-sleep state and ambient temperature and normal indexes of autonomic modulation at 37-42weeks of age despite a progressive somatic motor dysfunction, which includes impairments of walking ability (the ability to walk on a narrow path was impaired in 80% of mice at 34-38weeks of age) and subtle breathing derangements. Only late in the development of the disease phenotype did Plp-FLAG-LMNB1 mice develop a structural deficit of sympathetic noradrenergic fibers, with a 38% decrease in fiber profiles in the kidneys at 44-47weeks of age. We demonstrate that while the Plp-FLAG-LMNB1 mouse model recapitulates the age-dependent motor dysfunction of ADLD, it does not show signs of early autonomic cardiovascular dysfunction, raising the possibility that oligodendrocyte dysfunction may not be sufficient to cause the full spectrum of clinical features present in ADLD.Entities:
Keywords: Arterial pressure; Breathing; Gait; Heart rate; Lamin; Leukodystrophy; Mice; Oligodendrocyte; Sleep; Sympathetic
Mesh:
Substances:
Year: 2017 PMID: 29262292 PMCID: PMC5809293 DOI: 10.1016/j.expneurol.2017.12.006
Source DB: PubMed Journal: Exp Neurol ISSN: 0014-4886 Impact factor: 5.330